Novartis Atrasentan Phase III Data Show Clinically Meaningful Proteinuria Reduction Further Advancing Company's IgA Nephropathy (IgAN) Portfolio
Drugs.com,
– Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an…